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CD8+ T cells are potent killers of infected cells and
tumors, specifically recognizing their targets through the
T cell receptor (TCR). While much has been revealed
about the activation of TCR signaling, negative regulation
of this pathway remains incompletely elucidated. We
report that Cish plays an inhibitory role in immunity to
infection and adoptive transfer of Cish-deficient CD8+
T cells eliminated established cancer. Cish deletion
resulted in augmented acute phospholipase Cg1 (PLCg1)
activation, Ca2+ flux, NFAT and NFkB activity, and cyto-
kine release. Conversely, Cish reconstitution decreased Ca2
+ flux, T cell polyfunctionality and PLCg1 accumulation in
microclusters. We found that Cish physically interacts with
PLCg1, targeting it for degradation following TCR engage-
ment. Our data reveals a central role for Cish as a negative
regulator of proximal TCR signaling and CD8+ T cell
immunity and identifies a new targetable interaction for
immune-based therapy of infectious disease and cancer.
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